| Pegasys (pegylated interferon α -2a) / Roche |
NCT00983853 / 2008-007995-81: Safety and Efficacy of Telaprevir in Combination With Peginterferon Alfa-2a and Ribavirin in Subjects Co-Infected With Hepatitis C Virus (HCV) and HIV |
|
|
| Completed | 2a | 62 | US, Europe | telaprevir or matching placebo, peginterferon alfa-2a, ribavirin (fixed dose), ribavirin (weight-based dose) | Vertex Pharmaceuticals Incorporated, Tibotec Pharmaceutical Limited | Hepatitis C, HIV Infections | 03/12 | | | |
|
|
|
ROCO2, NCT00221650: Treatment of Chronic Hepatitis C With PEG Interferon alfa2a and Ribavirin in HIV-Infected Patients |
|
|
| Completed | 2 | 17 | Europe | Peginterferon alfa2a, Ribavirin | University Hospital, Bordeaux, Hoffmann-La Roche, Ministry of Health, France | HIV Infections, Hepatitis C, Chronic, Treatment Failure | | 06/04 | | |
NCT00196586: Efficacy and Safety of Addition of IL-2 to Pegylated Interferon Alpha 2a and Ribavirin in HIV/HCV Coinfected Patients |
|
|
| Completed | 2 | 75 | Europe | Interleukin 2, pegylated interferon alpha 2a, ribavirin | French National Agency for Research on AIDS and Viral Hepatitis, Hoffmann-La Roche | HIV Infections, Chronic Hepatitis C | | 11/06 | | |
NCT00078442: Safety and Tolerability of Pegylated Interferon (PEG-IFN) Alfa-2a in HIV Infected People |
|
|
| Completed | 2 | 12 | US | Pegylated interferon alfa-2a | National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 01/07 | | | |
PIFNPK, NCT00085917: Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients |
|
|
| Completed | 2 | 29 | US | Double dose pegylated interferon with weight based Ribavirin, Pegasys, standard dose pegylated interferon alfa -2a and ribavirin, pegasys | National Institute of Allergy and Infectious Diseases (NIAID) | Hepatitis C, HIV Infections | 11/08 | 11/08 | | |
NCT00594880: Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection |
|
|
| Completed | 2 | 23 | US | Pegylated Interferon-alpha 2a, 180 mcg/week sc, Pegasys, Pegylated Interferon-alpha 2a, 90 mcg/week sc | The Wistar Institute, National Institutes of Health (NIH), National Institute of Allergy and Infectious Diseases (NIAID), Hoffmann-La Roche | HIV Infections | 11/10 | 05/11 | | |
TelapreVIH, NCT01332955: Telaprevir in HIV-HCV Coinfected Patients Who Had Previously Failed a Peginterferon-Ribavirin Regimen |
|
|
| Completed | 2 | 70 | Europe | Telaprevir, VX-950, pegIFN alfa-2a, peginterferon alfa-2a, Pegasys®, Ribavirin, Copegus®, Rebetol® | ANRS, Emerging Infectious Diseases, Janssen-Cilag Ltd. | Hepatitis C, Chronic, HIV Infection | 09/13 | 09/13 | | |
|
|
|
|
|
